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Pharmacological Evidence Suggests that the Lysozyme/PACAP Receptor
of Tetrahymena thermophila is a Polycation Receptor

Michael KEEDY, Nathan YORGEY, Jeremy HILTY, Angela PRICE, David HASSENZAHL,
and Heather KURUVILLA
Cedarville University, Department of Science and Mathematics, Cedarville, U.S.A.
Summary. Pituitary adenylate cyclase activating polypeptide (PACAP) is a peptide hormone that exists in two biologically active forms:
PACAP-38 and PACAP-27. Several types of PACAP receptors have been characterized, and these have been classified into three families:
the VPAC1, the VPAC2, and the PAC1 receptors. In this study, we used in vivo behavioral assays along with pharmacological inhibitors
to investigate the behavior of the lysozyme/PACAP receptor in Tetrahymena. This receptor behaves like a PAC1 receptor in some respects;
however, PACAP 6-38 serves as an agonist, rather than an antagonist, for this receptor. These results are consistent with the existence of
a generalized polycation receptor rather than a PACAP-specific receptor.
Key words: chemorepellent, G-protein, PACAP-38, PKA, PKC, polycation receptor, Tetrahymena.
Abbreviations: BIS IV - bisindolylmaleimide IV; cAMP - adenosine 3’5’monophosphate; cGMP - guanosine 3’5’ monophosphate;
EC50 - concentration of repellent which causes 50% avoidance; EIA - enzyme-linked immunoassay; GDP-β-S - guanosine 5’-O(2-thiodiphosphate); IP3 - inositol 1,4,5 trisphosphate; PACAP - pituitary adenylate cyclase activating polypeptide; PKA - cAMPdependent protein kinase; PKC - protein kinase C; Rp-cAMPs - Rp-adenosine-3’, 5’ cyclic monophosphorothioate.

INTRODUCTION
Pituitary adenylate cyclase activating polypeptide
(PACAP) is a peptide hormone derived from a larger
polypeptide precursor. This peptide exists in two biologically active forms: a 38-amino acid peptide, PACAP-38
(Miyata et al. 1989), and an N-terminal amidated
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27-amino acid peptide, PACAP-27 (Miyata et al. 1990).
Both forms of this peptide are polycations at physiological pH. Receptors for this peptide have been found in
nearly every organ in the body (Vaudry et al. 2000). The
nearly ubiquitous nature of this peptide in mammalian
systems makes it an interesting ligand to study in other
cell systems. PACAP-38 has previously been shown to
act as a chemorepellent in Tetrahymena thermophila
(Mace et al. 2000, Hassenzahl et al. 2001).
Since the initial discovery of PACAP, several types of
receptors have been identified and classified based on
their affinities for the following ligands: PACAP-38,
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PACAP-27, vasoactive intestinal peptide (VIP), and
other members of the same peptide hormone superfamily. Three receptor classes have been identified so far:
the VPAC1 receptor, the VPAC2 receptor, and the PAC1
receptor (Harmar et al. 1998). Of these three receptor
types, previously obtained pharmacological data
(Hassenzahl et al. 2001) suggest that the Tetrahymena
receptor may share some characteristics with the PAC1
class of receptors in terms of the second messenger
pathways utilized. The pathways through which previously identified PAC1 receptors signal include cyclic
AMP (cAMP) as well as inositol trisphosphate (IP3) and
diacylglycerol (DAG)-mediated activation of protein kinase C (PKC) (Delporte et al. 1995, Hahm et al. 1998).
Two forms of the PAC1 receptor have been identified. Type IA receptors have an equal affinity for
PACAP-38 and PACAP-27, while type IB receptors
have a higher affinity for PACAP-38 than for
PACAP-27 (Harmar et al. 1998, Robberecht et al.
1991). Both types receptors have an affinity for VIP that
is about 1000 times less than the affinity for PACAP-38.
In addition, PAC1 receptors are selectively inhibited by
the antagonist PACAP 6-38, a fragment of PACAP-38
that binds to the receptor but does not activate the
second messenger pathway (Harmar et al. 1998). These
pharmacological profiles have not previously been evaluated in Tetrahymena.
Previous work in Tetrahymena has demonstrated
that the lysozyme response is mediated through a receptor that shows specific, saturable binding (Kuruvilla et
al. 1997). The receptor has also been isolated and
characterized electrophoretically as a 42 kD protein
(Kuruvilla and Hennessey 1998). Adaptation studies
with PACAP-38 have shown that cells exposed to
lysozyme for at least 10 min no longer show avoidance
to PACAP- 38 and vice versa (Mace et al. 2000). The
fact that both lysozyme and PACAP are polycations,
combined with the previously mentioned adaptation data,
suggests that these two ligands may utilize a common
receptor and second messenger pathways.
Recent work in our laboratory indicates that signaling
through the lysozyme/PACAP receptor of Tetrahymena
thermophila involves both cAMP production and the
activation of PKC (Hassenzahl et al. 2001). While this
suggests the possibility of PAC1 receptor involvement,
the potencies of PACAP-27, VIP, and the PAC1 receptor antagonist PACAP 6-38 have not been previously
tested in Tetrahymena. In our current study, we have
used in vivo behavioral assays as well as pharmacological inhibitors to suggest the presence of a receptor that

shares some characteristics with the PAC1 receptor
family, specifically, ligand potency and the use of common signaling pathways. However, there is one notable
difference: namely, the action of PACAP 6-38, an
antagonist to PAC1 receptors (Vaudry et al. 2000),
which acts as an agonist (chemorepellent) in our system.
These data suggest that the lysozyme/PACAP receptor
is probably a generalized, G-protein linked, polycation
receptor which signals through several second messenger pathways.

MATERIALS AND METHODS
Cell cultures
Tetrahymena thermophila B, strain SB715, a generous gift from
T. M. Hennessey (SUNY at Buffalo) was used throughout the study.
Cells were incubated in the axenic medium Dentler (1988) at 25°C for
48 h after inoculation without shaking and without addition of antibiotics.

Chemicals and solutions
As in earlier studies with lysozyme and PACAP (Kuruvilla et al.
1997, Mace et al. 2000, Hassenzahl et al. 2001), behavioral bioassays were carried out in a buffer containing 10 mM Trizma base,
0.5 mM MOPS, 50 µM CaCl2, pH 7.0. PACAP-38 was obtained
from Calbiochem, La Jolla, CA. PACAP-27 was obtained from Peninsula Laboratories, San Carlos, CA. PACAP 6-38 and VIP were
obtained from the American Peptide Co, Sunnyvale, CA. The
G-protein inhibitor guanosine 5’-O-(2-thiodiphosphate) (GDP-β-S)
was obtained from Alexis Biochemicals, San Diego, CA. The PKC
inhibitor Calphostin C and the PKA inhibitor Rp-cAMPs were
obtained from BIOMOL Research Laboratories, Plymouth Meeting,
PA. Another PKC inhibitor, BIS IV, was obtained from LC Laboratories, Woburn, MA. The cAMP EIA kit was obtained from Cayman
Chemical, Grand Rapids, MI. All other chemicals were obtained from
Sigma Chemical Company, St. Louis, MO.

Behavioral bioassays
In vivo behavioral assays were carried out as previously described
(Mace et al. 2000, Hassenzahl et al. 2001). Briefly, cells were first
washed twice in the assay buffer and then transferred to the first well
of a 3-well spot microtiter plate. Individual cells were then transferred, using a micropipette, to a well containing either buffer or the
inhibitor being tested. If an inhibitor was being tested, cells were
adapted to the inhibitor for a minimum of 10 to 15 min before
individual cells were transferred to a third well containing a combination of the chemorepellent and the test concentration of inhibitor and
scored for avoidance (+ or -) for each trial. Cells were scored as (+) for
avoidance if they showed backward swimming, characterized by
jerky, backward motions, backward motions in a straight line, or
backward “tumbling”, with the cell rotating anterior-over-posterior
or spinning rapidly, like a fan blade. If no inhibitor was being tested,
cells were simply transferred from the buffer to a well containing the
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chemorepellent of interest and scored for avoidance (+ or -) for each
trial. The mean ± SD was calculated for a minimum of three trials and
was expressed as “ Cells Showing Avoidance, [%]”.

EIA assays
Enzyme-linked immunoassays (EIAs) for cAMP were performed
using an EIA kit from Cayman Chemical, Grand Rapids, MI, Catalog
Number 581001. Briefly, two-day old cell cultures were washed
twice in behavioral buffer and then placed into the same behavioral
buffer containing 1 mM theophylline. Cells were then exposed to
0.1 µM PACAP-38, PACAP-27, or PACAP 6-38, or simply left in
buffer. Aliquots of 1 ml, containing approximately 7.66E06 cells,
were immediately frozen in liquid nitrogen. Upon thawing, the cell
lysate was centrifuged at 12,500 g for 10 min to remove particulate
matter. The supernatant was acetylated according to the EIA kit
manufacturer’s instructions (diluted 1:100 for maximum performance
on the standard curve) and used for the EIA assay.

RESULTS
In vivo behavioral assays indicate that PACAP-38,
PACAP-27, and PACAP 6-38 all act with similar potencies as chemorepellents in Tetrahymena (Fig. 1). The
EC50 (concentration of repellent which causes 50% of

Fig. 1. PACAP-38, PACAP-27, PACAP 6-38, and VIP are effective
chemorepellents in Tetrahymena. Behavioral bioassays (see Materials and Methods) were used to show the concentration dependencies
for avoidance reactions to PACAP-38 (closed diamonds), PACAP-27
(closed triangles), PACAP 6-38 (closed circles), and VIP (closed
squares). The percentage of cells showing avoidance was determined
by observation of a single cell after transfer to the test solution. Each
trial consisted of ten cells, which were individually scored as to
whether or not avoidance occurred. Each point represents the mean ±
SD of ≥ 3 trials. Error bars, representing the standard deviation, are
shown for each point. The EC50 values for these repellents were
approximately 10 nM for PACAP-38, PACAP-27, and PACAP 6-38
and 10 µM for VIP.

cells to show avoidance) of all three compounds
was approximately 10 nM. VIP, which was also a
chemorepellent, was much less potent, with an EC50 of
approximately 10 µM, 1000 times higher than that of the
other three ligands (Fig. 1). The concentrations of
repellent necessary to elicit 100% avoidance was
0.1 µM for PACAP-38, PACAP-27, and PACAP 6-38,
and 100 µM for VIP (Fig. 1). These concentrations of
repellent were used in the adaptation studies (Fig. 2),
cross-adaptation studies (Table 1), inhibitor studies
(Table 2), and cAMP assays which follow.
Chemorepellent responses to 0.1 µM PACAP-38,
0.1 µM PACAP-27, 0.1 µM PACAP 6-38, and 100 µM
VIP all declined with time (Fig. 2). By four min, approximately 50% of the cells had adapted to the repellent,
while a baseline (≤ 20%) avoidance response was seen
at 10 min. Based on the behavior of Tetrahymena when
placed in buffer under our assay conditions (10-20%;
Kuruvilla et al. 1997, Mace et al. 2000, Hassenzahl
et al. 2001), it appears that cells are fully adapted after
10 min of exposure to the repellents. All of the ligands
showed a similar time course of adaptation (Fig. 2).
As seen in previous studies with other repellents in
Tetrahymena, adaptation to all of the repellents could be
reversed by placing cells in buffer for about 10 min
before reintroducing them to the repellent (unpublished
observations; Kuruvilla et al. 1997).

Fig. 2. Adaptation to PACAP-38 (closed diamonds), PACAP-27
(closed triangles), PACAP 6-38 (closed circles), and VIP (closed
squares) all occurred over a similar time period (approximately
10 min), consistent with a common signaling mechanism. Each point
represents the mean ± SD of ≥ 3 trials. Error bars, representing the
standard deviation, are shown for each point.
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Table 1. Cross-adaptation between members of the VIP/PACAP family.
PACAP-38
PACAP-38
PACAP-27
PACAP 6-38
VIP

16.6
16.6
20.0
20.0

±
±
±
±

5.8
5.8
5.0
5.0

PACAP-27
20.0
16.6
20.0
20.0

±
±
±
±

PACAP-6-38

5.0
5.8
5.0
5.0

13.3
20.0
13.3
16.6

±
±
±
±

VIP

5.8
5.0
5.8
5.8

20.0
20.0
16.6
20.0

±
±
±
±

5.0
5.0
5.8
5.0

Means ± SD for ≥ 3 trials of 10 cells are listed. Each cell was adapted to the chemorepellent for 10 min before testing for cross-adaptation
in a different repellent. In all experiments, adaptation to one chemorepellent in the VIP/PACAP family effectively eliminated avoidance to
the other repellents in the family (avoidance in buffer alone under our assay conditions ranges from 10-20% (Kuruvilla et al. 1997, Mace
et al. 2000).

Table 2 Effect of various pharmacological inhibitors upon avoidance behavior in various members of the VIP/PACAP family.

PACAP-38, 0.1 µM
PACAP-27, 0.1 µM
PACAP 6-38, 0.1 µM
VIP, 100 µM

No inhibitor

GDP-β-S
1mM

Rp-cAMPs
50 µM

Calphostin C
10 µM

100 ± 0.0
100 ± 0.0
100 ± 0.0
96.6 ± 5.8

16.6 ± 5.8
13.3 ± 5.8
6.6 ± 5.8
20.0 ± 5.0

10 ± 5.0
10 ± 0.0
16.6 ± 5.8
20.0 ± 5.0

16.6
16.6
20.0
20.0

±
±
±
±

5.8
5.8
5.0
5.0

BIS IV
50 µM
20.0
16.6
16.6
20.0

±
±
±
±

5.0
5.8
5.8
5.0

Neomycin
5 µM
16.6
16.6
20.0
20.0

±
±
±
±

5.8
5.8
5.0
5.0

Means ± SD for ≥ 3 trials of 10 cells are listed. Each cell was incubated with the inhibitor for 10 min before testing for avoidance in the
chemorepellent. In all experiments, exposure to the pharmacological inhibitor nearly eliminated avoidance to the chemorepellent (avoidance
in buffer alone ranges from 10-20% under these assay conditions; Kuruvilla et al. 1997, Mace et al. 2000).

Cross-adaptation studies (Table 1) were also conducted to determine whether a cell adapted to one
chemorepellent in the VIP/PACAP family would also be
adapted to the other peptides in the family. Cells were
first adapted to either 0.1 µM PACAP-38, 0.1 µM
PACAP-27, 0.1 µM PACAP 6-38, or 100 µM VIP for
10 min and then exposed to one of the other three
repellents. In all cases, adaptation to one repellent
reduced avoidance to the other three repellents to baseline
levels of 10-20% (Table 1).
Several potent and specific pharmacological inhibitors
of second messenger pathways have been effective in
eliminating avoidance to PACAP-38 in Tetrahymena
(Mace et al. 2000, Hassenzahl et al. 2001). These
compounds were tested using in vivo behavioral assays
in order to determine whether the same second messenger pathways are involved in the signaling of the other
ligands in the VIP/PACAP family (Fig. 2). The concentrations of inhibitors used in the current assay were
based on previously published data (Mace et al. 2000,
Hassenzahl et al. 2001).

The G-protein inhibitor, 1 mM GDP-β-S (Hassenzahl
et al. 2001), effectively eliminated avoidance to 0.1µM
PACAP-38, 0.1µM PACAP-27, 0.1µM PACAP 6-38,
and 100 µM VIP (Table 2), lowering avoidance in all
cases to the baseline avoidance of 10-20%. A cAMP
analogue and competitive inhibitor of PKA, 50 µM
Rp-cAMPs (Hassenzahl et al. 2001), also eliminated
avoidance to all four chemorepellents, as did two PKC
inhibitors, 10 µM Calphostin C (Hassenzahl et al. 2001),
and 50 µM BIS IV (Hassenzahl et al. 2001), (Table 2).
A competitive inhibitor of the lysozyme receptor (Kuruvilla
et al. 1997) and an inhibitor of the PACAP-38 response
(Mace et al. 2000), 5 µM neomycin sulfate, effectively
eliminated the avoidance response to 0.1µM PACAP38, 0.1µM PACAP-27, 0.1µM PACAP 6-38, and
100 µM VIP (Table 2).
Indirect determination of cytosolic cAMP levels was
performed by EIA. These preliminary data (N=2) suggest that detectable levels of cAMP are present even in
control cells (7.73 ± 0.02E-06 picomoles/cell). Exposure
to PACAP-38 raised the cAMP level to 255% of the
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control level (1.96 ± 0.11E-05 picomoles/cell), and
PACAP-27 caused an increase in cAMP levels to 239%
of the control level (1.85 ± 0.12E-05 picomoles/cell).
Exposure to PACAP 6-38 caused a lesser increase,
raising the level of cAMP to 131% of control levels
(1.01 ± 0.08E-05 picomoles/cell). Although these data
are preliminary, they are consistent with the Rp-cAMPs
data mentioned above.

DISCUSSION
PAC1 receptors are characterized by a number of
common features, including a low affinity for VIP,
signaling through cAMP and PKC, and inhibition by the
PACAP fragment PACAP 6-38. Data from in vivo
behavioral assays in Tetrahymena (Fig. 1) indicates that
the potency of PACAP-38 and PACAP-27 is nearly
identical, and the potency of VIP is nearly 1000 times
lower than that of PACAP. These results are consistent
with signaling through a PAC IA receptor. However,
PACAP 6-38 acted as a repellent in our assay (Fig. 1)
rather than an antagonist of receptor activity. This is in
clear contrast to other systems where PACAP 6-38
serves as an antagonist to the PAC1 receptor, binding to
the receptor but not activating the second messenger
pathway (Harmar et al. 1998). However, PACAP 6-27,
also considered a competitive inhibitor of the PACAP
receptor, has been shown to stimulate serotonin release
from rat peritoneal mast cells (Seebeck et al. 1998). In
this case, a receptor-independent mechanism of
G-protein activation has been proposed. We have found
that PACAP 6-27 is also an effective chemorepellent in
our system (unpublished data), with potency nearly
indistinguishable from PACAP 6-38. While a receptorindependent mechanism of signaling such as the one
proposed for rat peritoneal mast cells is also possible in
our system, the high potency of PACAP 6-38, which is
nearly equivalent to that of PACAP-38 and PACAP-27,
along with the shape of the activation curve, is more
consistent with the existence of a receptor, linked to a
G-protein. Use of common signaling pathways for all the
ligands being studied (PACAP-38, PACAP-27, PACAP
6-38, and VIP) also supports the hypothesis that a
common receptor is being used.
Time course studies of in vivo behavioral adaptation
show a similar kinetic for all four repellents being tested.
This result is consistent with the hypothesis that PACAP-

38, PACAP-27, PACAP-6-38, and VIP are all signaling
through a common receptor. Adaptation occurs over a
fairly short time period (about 10 min) and is reversible.
These data are consistent with an adaptation mechanism
such as modification of the receptor or second-messenger pathway rather than a mechanism such as receptormediated endocytosis, which would require a longer
period of time for adaptation and recovery or deadaptation. In the case of lysozyme, which appears to
work through the same receptor as PACAP-38 (Mace
et al. 2000), receptor-mediated endocytosis is not the
mechanism of adaptation (Cantor et al. 1999). Our
current data support these earlier findings.
Cross-adaptation studies (Table 1) are also consistent
with the hypothesis that all four ligands being tested
(0.1 µM PACAP-38, 0.1 µM PACAP-27, 0.1 µM PACAP
6-38, and 100 µM VIP) share a common receptor and/
or second messenger pathway. Adaptation to any one of
the ligands in the VIP/PACAP family results in a lack of
responsiveness to any of the other ligands, resulting in a
baseline avoidance of 10-20%, similar to that seen in
buffer alone (Kuruvilla et al. 1997, Mace et al. 2000).
The polycation, lysozyme, is a chemorepellent in
Tetrahymena (Kuruvilla et al. 1997, Kuruvilla and
Hennessey 1998). The lysozyme receptor has been
purified by affinity chromatography, and a polyclonal
antibody has been raised against the purified protein
(Kuruvilla and Hennessey 1998). This antibody, along
with a competitive inhibitor of the lysozyme receptor
neomycin sulfate (Kuruvilla et al. 1997, Kuruvilla and
Hennessey 1998) has been used to show that
PACAP-38 and lysozyme share a common receptor in
Tetrahymena (Mace et al. 2000). Avoidance to PACAP38 may also be inhibited by the G-protein inhibitor
GDP-β-S, the cAMP analogue Rp-cAMPs, and the
PKC inhibitors Calphostin C and BIS IV (Hassenzahl et
al. 2001). These potent, specific inhibitors can be effectively used to determine involvement of specific enzymes/receptors in the in vivo behavioral response of
Tetrahymena.
In vivo behavioral assays done with 0.1 µM
PACAP-38, 0.1 µM PACAP-27, 0.1 µM PACAP 6-38,
or 100 µM VIP gave approximately 100% avoidance in
all cases (Table 2). The G-protein inhibitor 1 mM
GDP-β-S reduced avoidance to near the baseline response of ~10-20% in all cases (Table 2), implicating
G-protein involvement in the signaling pathway. This is
consistent with previous results for PACAP-38 and
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lysozyme, which appear to share a receptor and signaling pathways (Mace et al. 2000, Hassenzahl et al.
2001).
The cAMP analogue, 50 µM Rp-cAMPs, also inhibited avoidance to 0.1 µM PACAP-38, 0.1 µM PACAP27, 0.1 µM PACAP 6-38, and 100 µM VIP (Table 2).
These data are also consistent with what has been seen
for PACAP-38 and lysozyme (Hassenzahl et al. 2001).
This indicates that cAMP is involved in signaling, possibly as an activator of PKA, or perhaps in another
capacity, such as opening a plasma membrane calcium
channel. A calcium influx has previously been implicated
in the response of Tetrahymena to lysozyme (Kuruvilla
and Hennessey 1998). These data also support the
hypothesis of a common receptor/signaling pathway
used by all four ligands.
Preliminary data from EIA experiments measuring
the concentration of cAMP in the cytosol after PACAP
stimulation showed that all PACAP isoforms tested
stimulate cAMP production above control levels. This is
consistent with our current Rp-cAMPs data, which
suggests cAMP involvement in avoidance, as well as
data from previous studies (Hassenzahl et al. 2001).
Interestingly, PACAP 6-38, a PACAP receptor antagonist in many systems, caused less of an increase in
cAMP production than the native PACAP forms
(PACAP-38 and PACAP-27). Since the data are sparse,
repeated studies will be necessary to determine whether
this pattern is consistent. PACAP 6-38 was as potent an
agonist in our system as were the native forms of
PACAP, and future experiments continue to show lower
cAMP levels elicited by PACAP 6-38, this would suggest that the high cAMP levels caused by the native
forms of PACAP may not be necessary or sufficient to
cause avoidance. The data discussed below implicate
the PKC pathway as an integral part of avoidance, and
recent data from our laboratory suggest that PKG may
be important as well (unpublished observations). Clearly,
cAMP is not the only essential component of this
repellent pathway.
As seen in Table 2, the PKC inhibitors 10 µM
Calphostin C and 50 µM BIS IV effectively reduced
avoidance to 0.1 µM PACAP-38, 0.1 µM PACAP-27,
0.1 µM PACAP 6-38, and 100 µM VIP to near the
baseline avoidance of 10-20%. This is consistent with
previous results seen for PACAP-38 and lysozyme
(Hassenzahl et al. 2001) and implicates PKC in the
avoidance of chemorepellents in the PACAP family.
These data also support the hypothesis of a shared
second messenger pathway used by all four ligands.

Neomycin sulfate has been shown to be a competitive
inhibitor of lysozyme binding to its receptor in Tetrahymena (Kuruvilla et al. 1997, Kuruvilla and Hennessey
1998) as well as an inhibitor of PACAP-38 binding
(Mace et al. 2000). In this assay, 5 µM neomycin sulfate
reduced avoidance to 0.1 µM PACAP-38, 0.1 µM
PACAP-27, 0.1 µM PACAP 6-38, and 100 µM VIP to
near the baseline of 10-20%. This, too, is consistent with
previous results and supports the hypothesis that all four
of these ligands are working through the previously
identified lysozyme receptor. This low (5 µM) concentration of neomycin is 60 times lower than the concentration required to block calcium channels on the plasma
membrane of Paramecium (~300 µM; Gustin and
Hennessey 1988) and is consistent with previous inhibition data (Kuruvilla et al. 1997, Kuruvilla and Hennessey
1998, Mace et al. 2000).
In the current study, we have explored adaptation
kinetics, cross-adaptation of cells adapted to one ligand
and exposed to another, and the involvement of
G-proteins, cAMP, and PKC in signaling. While some of
the inhibitors used in our study may have pleiotropic
effects on the cell, when taken collectively, our data
suggest that PACAP avoidance in Tetrahymena occurs
through activation of a G-protein linked receptor. The
Tetrahymena receptor shows some similarities to previously described PAC1 receptors (Miyata et al. 1989,
Delporte et al. 1995, Hahm et al. 1998) in that it signals
through cAMP and PKC. However, the N-terminal
amino acids of PACAP do not appear to be required for
receptor activation, since PACAP 6-38 is as potent a
chemorepellent as PACAP-38 or PACAP-27. All of the
PACAP isoforms used in the assay, as well as VIP,
lysozyme (tested previously), and the lysozyme fragment
CB2 (Kuruvilla and Hennessey 1999) are positively
charged polypeptides. Interestingly, the more highly
charged molecules, such as PACAP (+ 12 at physiological pH), whose EC50 is 10 nM, are more potent than the
less highly charged molecules, such as CB2 (+ 4 at
physiological pH) whose EC50 is 100 nm (Kuruvilla and
Hennessey 1999, Mace et al. 2000). All of these data
are consistent with signaling of these repellents through
a polycation receptor, rather than through a specialized
PACAP receptor. This polycation receptor is likely the
previously isolated lysozyme receptor, based on the
cross-adaptation studies, similar inhibition profiles, and
the fact that the antibody raised against the lysozyme
receptor blocks PACAP avoidance (Kuruvilla and
Hennessey 1998, Mace et al. 2000, Hassenzahl et al.
2001). Molecular cloning of the receptor, perhaps using
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the amino acid sequence previously isolated from the
purified receptor preparation (Kuruvilla and Hennessey,
1998), will provide an important step toward identifying
sequences responsible for ligand binding and allow for
molecular characterization of this polycation receptor.
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